Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2013

01-07-2013 | Letter to the Editor

Topical evening primrose oil for reduction of bortezomib-induced skin reactions

Authors: Jutta Auberger, Stefan Vogt, Georg Hopfinger, Johannes Clausen, Richard Greil

Published in: Annals of Hematology | Issue 7/2013

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120:947–959PubMedCrossRef
2.
Dimoupoulos A, Tepos E (2010) Renal insufficiency and failure. Hematol Am Soc Hematol Educ Program 2010:431–436CrossRef
3.
San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–917PubMedCrossRef
4.
Aghajanian C, Soignet S, Dizon DS et al (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8(8):2505–2511PubMed
5.
Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431–440PubMedCrossRef
6.
Platzbecker U, Aul C, Ehninger G, Giagounidis A (2010) Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol 89:427–428PubMedCrossRef
7.
Belch JJ, Hill A (2000) Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 71:352S–356SPubMed
Metadata
Title
Topical evening primrose oil for reduction of bortezomib-induced skin reactions
Authors
Jutta Auberger
Stefan Vogt
Georg Hopfinger
Johannes Clausen
Richard Greil
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 7/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1656-2

Other articles of this Issue 7/2013

Annals of Hematology 7/2013 Go to the issue

Original Article

Thrombocytopenia in neonates: causes and outcomes

Letter to the Editor

Lymphomatoid granulomatosis masquerading as pneumonia

Original Article

Mitochondrial DNA variations in myelodysplastic syndrome

Original Article

The incidence of myelodysplastic syndromes in Western Greece is increasing

Original Article

Thrombosis following acute cytomegalovirus infection: a community prospective study

Original Article

Low expression of glucocorticoid receptor alpha isoform in adult immune thrombocytopenia correlates with glucocorticoid resistance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits